Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Operating Margin: 2022-2025

Historic Operating Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to 160.77%.

  • InMed Pharmaceuticals' Operating Margin fell 2535.00% to 162.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 167.40%, marking a year-over-year decrease of 2108.00%. This contributed to the annual value of 160.77% for FY2025, which is 1750.00% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Operating Margin of 160.77% as of FY2025, which was up 9.81% from 178.27% recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Operating Margin ranged from a high of 160.77% in FY2025 and a low of 1,584.71% during FY2022.
  • Its 3-year average for Operating Margin is 180.94%, with a median of 178.27% in 2024.
  • In the last 5 years, InMed Pharmaceuticals' Operating Margin surged by 138,094bps in 2023 and then tumbled by 1,750bps in 2025.
  • InMed Pharmaceuticals' Operating Margin (MRY) stood at 1,584.71% in 2022, then surged by 87bps to 203.77% in 2023, then increased by 13bps to 178.27% in 2024, then rose by 10bps to 160.77% in 2025.
  • Its Operating Margin stands at 160.77% for FY2025, versus 178.27% for FY2024 and 203.77% for FY2023.